OneMedNet Secures Oncology Data Deal, Bolsters AI Platform
Event summary
- OneMedNet has entered a collaboration with Onco-Innovations and its subsidiary, Inka Health, granting Inka Health access to OneMedNet’s iRWD™ platform.
- The agreement focuses on utilizing real-world data and AI to accelerate development of Onco-Innovations’ PNKP Inhibitor Technology for PTEN/SHP1-deficient cancers.
- Inka Health intends to integrate OneMedNet’s data into its SynoGraph™ AI platform for predicting cancer treatment success and safety.
- The deal highlights the intended use of OneMedNet’s iRWD™ platform for identifying rare patient populations at scale.
The big picture
This collaboration underscores the increasing importance of real-world data and AI in accelerating oncology drug development, a trend driven by the need to reduce costs and timelines in a sector facing mounting pressure. OneMedNet’s partnership with Onco-Innovations validates its iRWD™ platform, which leverages Palantir’s Foundry, and positions it to capitalize on the growing demand for regulatory-grade data and AI-powered analytics within the pharmaceutical industry. The deal also highlights the trend of smaller biotech firms leveraging established data platforms to augment their research and development capabilities.
What we're watching
- Platform Adoption
- The success of this collaboration hinges on Inka Health’s ability to effectively integrate OneMedNet’s iRWD™ platform into its existing workflows and demonstrate tangible benefits for drug development.
- Regulatory Scrutiny
- Increased reliance on real-world data in oncology drug development will likely draw greater regulatory scrutiny regarding data quality, bias mitigation, and validation of AI-driven insights.
- Competitive Landscape
- The growing demand for real-world data and AI solutions in oncology will intensify competition among platforms like OneMedNet’s iRWD™ and others, potentially impacting pricing and market share.
Related topics